



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

January 6, 2004

KIRK BAUMEISTER

(Name of applicant, assignee, or Registered Representative)

January 6, 2004

(Date of Signature)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Giles-Komar, Jill

Lamb, Roberta Mbow, M. Lamine

Serial No.: 10/644,308 Art Unit:

Filed: August 19, 2003 Examiner:

For : METHOD FOR GENERATING ANTIBODIES

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

X

accompanied by one of:

In accordance with §1.97(b), since this Information

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with [] the first or Second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10-0750/CEN309 USA NP/KB the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is

		Statement in Accordance with §1.97(e)
		(attached); or
		Please charge Deposit Account No. 10-
		0750/CEN309/KB the fee of $$180.00$ as set forth
		in §1.17(p).
	In a	ccordance with §1.97(d), this Information
Disclosur	e Sta	tement is being filed after the mailing date of
either a	Final	Action under §1.113 or a Notice of Allowance
under §1	.311	but before the payment of the Issue Fee.
Applicant	(s) h	ereby petition(s) for consideration of this
Informati	on Di	sclosure Statement. Included are: Statement in
Accordanc	e wit	h §1.97(e) as set forth below and the fee of
<u>\$180.00</u> a	s set	forth in §1.17(p).
ш	_	
1449 are	_	sed herewith EXCEPT THAT:
1449 are	_	
1449 are	enclo	sed herewith EXCEPT THAT:
1449 are	enclo	sed herewith EXCEPT THAT: In view of the voluminous nature of references [list as appropriate], and the likelihood that
1449 are	enclo	sed herewith EXCEPT THAT: In view of the voluminous nature of references [list as appropriate], and the likelihood that
1449 are	enclo	sed herewith EXCEPT THAT: In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner,
1449 are	enclo	In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
1449 are	enclo	In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith. If any of the foregoing publications are not
1449 are	enclo	In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner copies are not enclosed herewith. If any of the foregoing publications are not available to the Examiner, Applicant will
□ 1449 are	enclo	In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith. If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's
	enclo	In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith. If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
□ patent li	enclo Copi terat	In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner copies are not enclosed herewith. If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request. es of only foreign patent documents and non-

enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).

☐ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CEN309/KB. This form is submitted in triplicate.

patent applications which may be deemed relevant, which are

listed on the attached Submission Under MPEP 609 D.

Respectfully submitted,

KÍRK BÄUMEISTER Reg. No. 33,833

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (610) 240-8465 DATED: January 6, 2004



PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to response

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

and to a confection of miornianon unless it disp	nays a vand OMB control number.
Application Number	10/644,308
Filing Date	AUGUST 19, 2003
First Named Inventor	JILL GILES-KOMAR
Group Art Unit	
Examiner Name	
Attorney Docket Number	CEN 309 USA NP

				O.O. I ATENT DOCUMENTO		
		U.S. Patent Document			Data of Bublication	Bassa Calumna Linea
Examiner Cite Initials No.1	Cite	Kind Code ²		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages
	No. ¹	Number	(if known)	or ched boddheric	mm-dd-yyyy	or relevant figures appear
				•		
-						
	·					

LLC DATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document Name of Patentee or where relevant Examiner Cite passages or relevant mm-dd-yyyy Applicant of Cited Document Initials figures appear Number⁴ KindCode5

Examiner	Date	
Signature	Considered	
*CVALABLED	ADED AGO D	P. A

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 2

in journal of the control of the con
10/644,308
AUGUST 19, 2003
Jill Giles-Komar
CEN 309 USA NP

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item	2
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T²
Initials*	No. ¹	publisher, city and/or country where published	
		LONBERG ET AL, "Antigen-specific human antibodies from mice comprising four distinct genetic modifications," Letter to Nature, 1994, 856-859, Vol. 368.	
		GREEN, LARRY, "Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies," Journal of Immunological Methods, 1999, 11-23, Vol. 231.	
		LYMAN ET AL, "Molecular Cloning of a Ligand for the flt3/flk-2 Tyrosine Kinase Receptor: A Proliferative Factor for Primitive Hematopoietic Cells," Cell, 1993, 1157-1167, Vol. 75.	
		MARASKOVSKY ET AL, "Dramatic Increase in the Numbers of Functionally Mature Dendritic Cells in Flt3 Ligand-treated Mich: Multiple Dendritic Cell Subpopulations Identified," J. Exp. Med., 1996, 1953-1962, Vol. 184, The Rockefeller University Press.	
		LE BON ET AL, "Type I Interferons Potently Enhance Humoral Immunity and Can Promote Isotype Switching by Stimulating Dendritic Cells In Vivo," Immunity, 2001, 461-470, Vol. 14, Cell Press.	
		COHEN ET AL, "Modulating the immune response to genetic immunization," J. Faseb, 1998, 1611-1626, Vol. 12.	
		ROBINSON, HARRIET, "DNA Vaccines: Basic mechanism and immune responses (Review)," International Journal of Molecular Medicine, 1999, 549-555, Vol. 4.	
		DONNELLY ET AL, "DNA Vaccines," Dev. Biol. Stand., 1998, 43-53, Vol. 95.	
	L		
		·	
	-		
	1		
,			
	<u> </u>		
	 		_

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Alexandria, VA 22313-1450jn.

Office, Alexandria, VA 22313-1450jn.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop: IDS – Patent Applications, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

1

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.